Livazo®/Livalo® pitavastatin is a fully synthetic and highly potent statin available across Asia, Europe, Latin America and North America. It is indicated for the reduction of elevated total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in adult patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia, and combined (mixed) dyslipidemia, when response to dietary and other non-pharmacological measures are inadequate.1
Since its 2003 launch in Japan, pitavastatin has accumulated millions of patient-years of exposure2 and has confirmed its place in the statin armamentarium, particularly for patients who require high-density lipoprotein cholesterol (HDL-C) raising or where poly-pharmacy exists, with a risk of drug-to-drug interactions. More recently, a study conducted in Japan demonstrated that pitavastatin did not increase the risk of developing diabetes in a large group of patients with impaired glucose tolerance.3
Pitavastatin is marketed in several European countries by our partner Recordati (primarily under the Livazo® brand name). For more information on ordering pitavastatin or for patient materials, please get in touch with our partners.
- Medicines and Healthcare products Regulatory Agency Public Assessment Report. Available at http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con096843.pdf.
Accessed November 2013.
- Data on file.
- Odawara M, et al. European Association for the Study of Diabetes 2013. Abstract 128. Available at http://www.easdvirtualmeeting.org/resources/3645. Accessed November 2013.